Sera Prognostics, Inc (SERA) Fair Value & Analysis
Healthcare · US · Market cap $72.2M
Sera Prognostics, Inc
SERA · US
Fair value as of: Jun 25, 2026
From 1 valuation models · updated 10 days ago
Fair value updated Jun 25, 2026 — revised from $8.89 to $0.3700 (−95.8%) since Jun 24, 2026. Share price −2.0% over the past month.
Price vs Fair Value (12 months)
12‑month range $1.43 – $3.38 · fair‑value band $0.2500 – $0.4700 · the $1.80 price screens above the $0.3700 fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sera Prognostics, Inc (SERA) currently trades at $1.80, while our model-based Fair Value estimate is $0.3700 — implying the stock looks roughly 79.4% overvalued today. We read business quality at 29/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $57.0K. Revenue declined 63.2% year over year. It earns a return on equity of -39.6%. The balance sheet holds a net cash position of $1.6M. Fundamentals as of Jun 25, 2026
Our scenario range runs from $0.2500 (bear case) to $0.4700 (bull case); at $1.80, the current price sits above that range. The share trades about 56% below its 52-week high and 15% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside — at -79%, SERA screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sera Prognostics, Inc reported revenue of $81.0K in FY2025 versus $82.0K in FY2021, a compound −0.3%/yr. Reported net income was −$31.9M in FY2025.
Is SERA fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 82.40 MXN | -95% |
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDT | $81.67 | $60.02 | -27% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.98 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
| GE HealthCare Technologies Inc GEHC | $61.99 | $48.34 | -22% |
| DexCom, Inc DXCM | $69.07 | $65.56 | -5% |
| Koninklijke Philips N.V 1PHIA | €24.31 | €9.97 | -59% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥143.50 | ¥111.50 | -22% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sera Prognostics, Inc (SERA) undervalued?
What is the fair value of SERA?
What is the quality score of SERA?
What is the revenue of Sera Prognostics, Inc (SERA)?
What is the net profit margin of SERA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.